Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 16/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LOX | P28300 | 1/20 | 0.46 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.46 |
| ▸ | LOXL4 | Q96JB6 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13104005 | 0.87 | CES2 (1.00) | CES2KDM4ERAB9AL3MBTL1LOX | |
| SCHEMBL4059748 | 0.83 | CES2 (0.82) | CES2KDM4ERAB9AL3MBTL1LOX | |
| SCHEMBL19499378 | 0.81 | CES2 (0.89) | CES2KDM4ERAB9AL3MBTL1LOX | |
| SCHEMBL19506499 | 0.76 | CES2 (0.78) | CES2KDM4ERAB9AL3MBTL1LOX | |
| SCHEMBL17357741 | 0.76 | CES2 (0.78) | CES2KDM4ERAB9AL3MBTL1LOX | |
| SCHEMBL4663223 | 0.70 | CES2 (0.68) | CES2RAB9ALOXLOXL3LOXL4 | |
| SCHEMBL419526 | 0.69 | CES2 (0.68) | CES2KDM4ERAB9ALOXLOXL3 | |
| SCHEMBL29718871 | 0.69 | CES2 (1.00) | CES2 | |
| SCHEMBL6042079 | 0.69 | CES2 (0.67) | CES2KDM4ERAB9ALOXLOXL3 | |
| SCHEMBL4663174 | 0.69 | CES2 (0.67) | CES2KDM4ERAB9ALOXLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | CES2 221/4885KDM4E 2978/4885RAB9A 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.